1. Home
  2. Analysis
  3. Cabergoline
  4. Agranulocytosis

Cabergoline and Agranulocytosis - a phase IV clinical study of FDA data

Summary:

Agranulocytosis is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Lioresal, and have Parkinson's disease.

The phase IV clinical study analyzes which people have Agranulocytosis when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Agranulocytosis?

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection) is found to be associated with 2,325 drugs and 3,597 conditions by eHealthMe. Check the latest studies of Agranulocytosis.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 32 people (0.54%) have Agranulocytosis.

Could Cabergoline cause Agranulocytosis?

Among these 32 people:

How long have people been on Cabergoline when they have Agranulocytosis? *

  • < 1 month: 33.33 %
  • 1 - 6 months: 33.33 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 33.33 %
  • 2 - 5 years: 0.0 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

What is the gender of people who have Agranulocytosis when taking Cabergoline? *

  • female: 64.52 %
  • male: 35.48 %

What is the age of people who have Agranulocytosis when taking Cabergoline? *

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 19.23 %
  • 40-49: 11.54 %
  • 50-59: 34.62 %
  • 60+: 34.62 %

What are other drugs people take besides Cabergoline? *

  1. Lioresal: 5 people, 15.62%
  2. Unasyn: 4 people, 12.50%
  3. Signifor Lar: 4 people, 12.50%
  4. Artane: 4 people, 12.50%
  5. Sucralfate: 3 people, 9.38%
  6. Allopurinol: 3 people, 9.38%
  7. Aricept: 3 people, 9.38%
  8. Pramipexole Dihydrochloride: 3 people, 9.38%
  9. Paxil: 3 people, 9.38%
  10. Carbidopa And Levodopa: 3 people, 9.38%

What are other side effects people have besides Agranulocytosis? *

  1. Fever: 6 people, 18.75%
  2. White Blood Cell Count Decreased: 5 people, 15.62%
  3. Thrombocytopenia (decrease of platelets in blood): 5 people, 15.62%
  4. Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 15.62%
  5. Leukopenia (less number of white blood cells in blood): 4 people, 12.50%
  6. Viral Infection: 4 people, 12.50%
  7. Urinary Tract Infection: 4 people, 12.50%
  8. Type 2 Diabetes: 4 people, 12.50%
  9. Back Pain: 4 people, 12.50%
  10. Diarrhea: 4 people, 12.50%

What are the existing conditions these people have? *

  1. Parkinson's Disease: 8 people, 25.00%
  2. Stress And Anxiety: 5 people, 15.62%
  3. Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 5 people, 15.62%
  4. High Blood Pressure: 4 people, 12.50%
  5. Dementia (madness): 4 people, 12.50%
  6. Depression: 4 people, 12.50%
  7. Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 4 people, 12.50%
  8. Nervous System Disorder (a general class of medical conditions affecting the nervous system): 4 people, 12.50%
  9. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 9.38%
  10. Growth Hormone Deficiency: 2 people, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Agranulocytosis?

- Check whether Agranulocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Agranulocytosis treatments and more:

How severe was Agranulocytosis and when was it recovered:

Expand to all the drugs that have ingredients of cabergoline:

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Agranulocytosis:

Browse all the conditions that are associated with Agranulocytosis:

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.